Document detail
ID

oai:arXiv.org:2407.14299

Topic
Computer Science - Distributed, Pa... Computer Science - Cryptography an... Physics - Data Analysis, Statistic...
Author
Fujihara, Akihiro
Category

Computer Science

Year

2024

listing date

7/24/2024

Keywords
byzantine data consensus blockchains blockchain distribution time block
Metrics

Abstract

Some blockchain networks employ a distributed consensus algorithm featuring Byzantine fault tolerance.

Notably, certain public chains, such as Cosmos and Tezos, which operate on a proof-of-stake mechanism, have adopted this algorithm.

While it is commonly assumed that these blockchains maintain a nearly constant block creation time, empirical analysis reveals fluctuations in this interval; this phenomenon has received limited attention.

In this paper, we propose a mathematical model to account for the processes of block propagation and validation within Byzantine fault-tolerant consensus blockchains, aiming to theoretically analyze the probability distribution of block time.

First, we propose stochastic processes governing the broadcasting communications among validator nodes.

Consequently, we theoretically demonstrate that the probability distribution of broadcast time among validator nodes adheres to the Gumbel distribution.

This finding indicates that the distribution of block time typically arises from convolving multiple Gumbel distributions.

Additionally, we derive an approximate formula for the block time distribution suitable for data analysis purposes.

By fitting this approximation to real-world block time data, we demonstrate the consistent estimation of block time distribution parameters.

;Comment: 9 pages, 4 figures, accepted to be published at the 7th IEEE International Conference on Blockchain (Blockchain 2024)

Fujihara, Akihiro, 2024, Theoretical Analysis on Block Time Distributions in Byzantine Fault-Tolerant Consensus Blockchains

Document

Open

Share

Source

Articles recommended by ES/IODE AI

Batoclimab as induction and maintenance therapy in patients with myasthenia gravis: rationale and study design of a phase 3 clinical trial
gravis myasthenia study clinical phase baseline improvement mg-adl 340 week trial placebo period mg maintenance qw